541 related articles for article (PubMed ID: 16650951)
21. Evaluation of the in vitro activity of 9 antimicrobials against bacterial strains isolated from patients in intensive care units in brazil: MYSTIC Antimicrobial Surveillance Program.
Mendes C; Hsiung A; Kiffer C; Oplustil C; Sinto S; Mimica I; Zoccoli C;
Braz J Infect Dis; 2000 Oct; 4(5):236-44. PubMed ID: 11063555
[TBL] [Abstract][Full Text] [Related]
22. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
[TBL] [Abstract][Full Text] [Related]
23. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
Zarakolu P; Hasçelik G; Unal S
Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
[TBL] [Abstract][Full Text] [Related]
24. Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program.
Korten V; Ulusoy S; Zarakolu P; Mete B;
Diagn Microbiol Infect Dis; 2007 Dec; 59(4):453-7. PubMed ID: 17888609
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the in vitro antimicrobial activity of cefepime compared to other broad-spectrum beta-lactams tested against recent clinical isolates from 10 Chinese hospitals. Chinese Antimicrobial Resistance Study Group.
Xu Y; Chen M; Biedenbach DJ; Deshpande LM; Jones RN
Diagn Microbiol Infect Dis; 1999 Oct; 35(2):135-42. PubMed ID: 10579094
[TBL] [Abstract][Full Text] [Related]
26. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates.
Turner PJ
Diagn Microbiol Infect Dis; 2009 Feb; 63(2):217-22. PubMed ID: 19070453
[TBL] [Abstract][Full Text] [Related]
27. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results.
Turner PJ
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):185-92. PubMed ID: 17945455
[TBL] [Abstract][Full Text] [Related]
28. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004).
Gales AC; Jones RN; Sader HS
Clin Microbiol Infect; 2006 Apr; 12(4):315-21. PubMed ID: 16524407
[TBL] [Abstract][Full Text] [Related]
29. Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003).
Rhomberg PR; Jones RN; Sader HS; Fritsche TR;
Diagn Microbiol Infect Dis; 2004 Aug; 49(4):273-81. PubMed ID: 15313533
[TBL] [Abstract][Full Text] [Related]
30. ['In vitro' activity of different antimicrobial agents on Gram-negative nonfermentative bacilli, excluding Pseudomonas aeruginosa and Acinetobacter spp].
Vay CA; Almuzara MN; Rodríguez CH; Pugliese ML; Lorenzo Barba F; Mattera JC; Famiglietti AM
Rev Argent Microbiol; 2005; 37(1):34-45. PubMed ID: 15991478
[TBL] [Abstract][Full Text] [Related]
31. Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003-2008.
Wang H; Chen M; Ni Y; Liu Y; Sun H; Yu Y; Yu X; Mei Y; Liu M; Sun Z; Chu Y; Hu Z; Huang X
Int J Antimicrob Agents; 2010 Mar; 35(3):227-34. PubMed ID: 20047820
[TBL] [Abstract][Full Text] [Related]
32. Comparison of in vitro activities of levofloxacin, ciprofloxacin, ceftazidime, cefepime, imipenem, and piperacillin-tazobactam against aerobic bacterial pathogens from patients with nosocomial infections.
Huang SS; Lee SC; Lee N; See LC; Tsai MH; Shieh WB
J Microbiol Immunol Infect; 2007 Apr; 40(2):134-40. PubMed ID: 17446961
[TBL] [Abstract][Full Text] [Related]
33. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections at a medical center in Taiwan: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) 2002-2006.
Chen WY; Jang TN; Huang CH; Hsueh PR
J Microbiol Immunol Infect; 2009 Aug; 42(4):317-23. PubMed ID: 19949755
[TBL] [Abstract][Full Text] [Related]
34. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006.
Zhanel GG; DeCorby M; Nichol KA; Wierzbowski A; Baudry PJ; Karlowsky JA; Lagacé-Wiens P; Walkty A; Mulvey MR; Hoban DJ;
Diagn Microbiol Infect Dis; 2008 Sep; 62(1):67-80. PubMed ID: 18513913
[TBL] [Abstract][Full Text] [Related]
35. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004.
Unal S; Garcia-Rodriguez JA
Diagn Microbiol Infect Dis; 2005 Dec; 53(4):265-71. PubMed ID: 16360550
[TBL] [Abstract][Full Text] [Related]
36. Surveillance of antimicrobial susceptibility of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in China: the 2002-2009 Study for Monitoring Antimicrobial Resistance Trends (SMART).
Yang Q; Wang H; Chen M; Ni Y; Yu Y; Hu B; Sun Z; Huang W; Hu Y; Ye H; Badal RE; Xu Y
Int J Antimicrob Agents; 2010 Dec; 36(6):507-12. PubMed ID: 21036547
[TBL] [Abstract][Full Text] [Related]
37. In vitro evaluation of cefepime and other broad-spectrum beta-lactams in Taiwan medical centers. The Taiwan Antimicrobial Resistance Study Group.
Biedenbach DJ; Johnson DM; Jones RN
Diagn Microbiol Infect Dis; 1999 Dec; 35(4):299-305. PubMed ID: 10668589
[TBL] [Abstract][Full Text] [Related]
38. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
[TBL] [Abstract][Full Text] [Related]
39. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001).
Mutnick AH; Rhomberg PR; Sader HS; Jones RN
J Antimicrob Chemother; 2004 Feb; 53(2):290-6. PubMed ID: 14711839
[TBL] [Abstract][Full Text] [Related]
40. Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group.
Jones RN; Pfaller MA; Doern GV; Erwin ME; Hollis RJ
Diagn Microbiol Infect Dis; 1998 Mar; 30(3):215-28. PubMed ID: 9572029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
